Why the study?
Does sacubitril-valsartan reduce serum uric acid and improve outcomes in patients with heart failure with preserved ejection fraction compared with valsartan?
Does sacubitril-valsartan reduce serum uric acid and improve outcomes in patients with heart failure with preserved ejection fraction compared with valsartan?
In patients with HFpEF, sacubitril-valsartan lowers serum uric acid levels compared to valsartan, a reduction that correlates with improved cardiovascular outcomes.
Answers are grounded in this paper and cite their sources.
Supports SUA reduction as a modifiable target in HFpEF; extends sacubitril-valsartan benefits beyond primary endpoints.
Serum uric acid independently predicted adverse outcomes in HFpEF. Sacubitril-valsartan reduced SUA and the initiation of related therapy compared with valsartan. Reductions in SUA were associated with improved outcomes.
No takes yet. Share an insight, caveat, or question.
Selvaraj et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: